Table 1 Comparison of baseline characteristics between two cohorts.
Characteristics | Our cohort, n (%) | Mayo cohort [12] |
|---|---|---|
Age (yrs), median (range) | 61 (27–89) | 64 (57–71) |
Sex, male | 590 (58.7) | 62% |
M protein | ||
IgG | 452 (45.0) | 62% |
IgA | 249 (24.8) | 25% |
IgD | 61 (6.1) | – |
LC | 215 (21.4) | 11% |
Non/oligosecretory | 27 (2.7) | – |
Biclonal | 1 (0.0) | – |
ISS stage | ||
I | 169 (16.8) | – |
II | 306 (30.4) | – |
III | 530 (52.7) | 33% |
R-ISS stage | ||
I | 118 (11.7) | 11% |
II | 624 (62.1) | 66% |
III | 263 (26.2) | 23% |
LDH, elevated | 265 (26.4) | 17% |
BMPCs, ≥ 30% (n = 562) | 358 (63.7) | 50 (30–70)a |
β2-MG, ≥ 5.5 μg/ml (n = 567) | 324 (57.1) | 32% |
Hemoglobin, ≤10 g/dL (n = 948) | 635 (67.0) | 33% |
Calcium, ≥ 1 mg/dL (n = 1003) | 143 (14.3) | 11% |
Creatinine, ≥2 mg/dL (n = 1004) | 261 (26.0) | 16% |
Bone disease (n = 963) | 887 (92.1) | – |
Extramedullary lesion (n = 960) | 193 (20.1) | – |
Albumin, <3.5 g/dL (n = 899) | 523 (58.2) | 48% |
Platelet, <100 × 109/L (n = 1002) | 149 (14.9) | 210 (162–262)a |
+1q | 521 (51.8) | 31% |
del(17p) | 113 (11.2) | 13% |
del(13q) (n = 978) | 412 (42.1) | 37%b |
del(1p) (n = 413) | 35 (8.5) | – |
IgH translocation | ||
t(11;14) | 130 (12.9) | 21% |
t(4;14) | 138 (13.7) | 10% |
t(14;16) | 22 (2.2) | 4% |
First-line treatment | ||
PI | 511 (50.8) | 31% |
IMiD | 177 (17.6) | 31% |
PI + IMiD | 317 (31.5) | 34% |
Transplant | 122 (12.1) | 55% |
